Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.

Mouse tumor cells transfected with syngeneic MHC class II genes are highly immunogenic in the autologous host, and induce a potent tumor-specific immunity against wild type tumor. Previous studies with sarcoma tumor cells expressing transfected class II gene products with truncated cytoplasmic domains suggested that during the process of tumor rejection costimulatory molecules are induced on the tumor cells, contributing to the cells' ability to stimulate immunity. In the present study we directly demonstrate that tumor cells containing full-length class II heterodimers are induced to express B7-1 and B7-2 costimulatory molecules during the rejection process. In contrast, tumor cells expressing class II heterodimers truncated for their cytoplasmic tails are not induced to express B7-1 and/or B7-2. Blocking the interaction of the induced costimulatory molecules with their corresponding receptors on T cells prevents tumor rejection. These results support the hypothesis that the cytoplasmic domain of the MHC class II molecule is involved in induction of costimulatory molecule expression, perhaps via intracellular signalling pathways. Because class II, B7 transfected tumor cells are such effective immunogens against ascites and solid tumors, they have also been tested in metastatic disease. K1735 and B16BL6 mouse melanomas, when transfected with syngeneic MHC class II and B7-1 genes, are significantly less metastatic than parental cells, and immunization with the transfectants protects against subsequent challenge with wild type tumor.

[1]  C. Benoist,et al.  Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[2]  P. Linsley,et al.  Functional expression of the costimulatory molecule, B7/BB1, on murine dendritic cell populations , 1992, The Journal of experimental medicine.

[3]  L. Glimcher,et al.  A functional role for signal transduction via the cytoplasmic domains of MHC class II proteins. , 1989, Journal of immunology.

[4]  G. Freeman,et al.  Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression , 1992, Nature.

[5]  J. Allison,et al.  Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.

[6]  R. Schwartz,et al.  Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. , 1989, Annual review of immunology.

[7]  K. Ozato,et al.  Hybridoma cell lines secreting monoclonal antibodies to mouse H-2 and Ia antigens. , 1980, Journal of immunology.

[8]  S. Ostrand-Rosenberg,et al.  Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. , 1991, Journal of immunology.

[9]  G. Freeman,et al.  Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. Greenberg,et al.  The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia. , 1990, Science.

[11]  J. Johnston,et al.  Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity , 1994, The Journal of experimental medicine.

[12]  P. Linsley,et al.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.

[13]  P. Greenberg Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. , 1991, Advances in immunology.

[14]  P. Stern,et al.  Natural history of HLA expression during tumour development. , 1993, Immunology today.

[15]  S. Swain T Cell Subsets and the Recognition of MHC Class , 1983, Immunological reviews.

[16]  L. Glimcher,et al.  Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice , 1995, The Journal of experimental medicine.

[17]  S. Ostrand-Rosenberg,et al.  Rejection of mouse sarcoma cells after transfection of MHC class II genes. , 1990, Journal of immunology.

[18]  P. Linsley,et al.  The role of the CD28 receptor during T cell responses to antigen. , 1993, Annual review of immunology.

[19]  L. Glimcher,et al.  Antigen presentation abrogated in cells expressing truncated Ia molecules. , 1989, Journal of immunology.

[20]  C. Janeway,et al.  Monoclonal antibodies specific for Ia glycoproteins raised by immunization with activated T cells: possible role of T cellbound Ia antigens as targets of immunoregulatory T cells. , 1984, Journal of immunology.

[21]  P. Greenberg,et al.  Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. , 1986, Journal of immunology.

[22]  I. Hart The selection and characterization of an invasive variant of the B16 melanoma. , 1979, The American journal of pathology.

[23]  B. Vogelstein,et al.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.

[24]  J. Buerstedde,et al.  The assignment of chain specificities for anti-Ia monoclonal antibodies using L cell transfectants. , 1986, Journal of immunology.

[25]  H. Ananthaswamy,et al.  Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. , 1993, Journal of immunology.

[26]  M. Kripke,et al.  Speculations on the role of ultraviolet radiation in the development of malignant melanoma. , 1979, Journal of the National Cancer Institute.

[27]  G. Powers,et al.  Monoclonal antibody 2D10 recognizes a novel T cell costimulatory molecule on activated murine B lymphocytes. , 1994, Journal of immunology.